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Background: Antibiotic-associated diarrhea (AAD) is a common adverse effect of antibiotic (AB) treatment. This
study aimed to measure the overall prevalence of AAD (including mild to moderate diarrhea) in hospitalized AB
treated patients, to investigate associated risk factors and to document AAD associated diagnostic investigations,
contamination control and treatment.
Methods: During 8 observation days (with time delay of 10–14 days between each observation day), all adult
patients hospitalized at an internal medicine ward of 4 Belgian participating hospitals were screened for AB use.
Patients receiving AB on the observation day were included in the study and screened for signs and symptoms of
AAD using a period prevalence methodology. Clinical data were collected for all AB users and AAD related
investigations and treatment were collected for the entire duration of AAD. Additionally, nurses noted daily the
frequency of all extra care associated to the treatment of the diarrhea.
Results: A total of 2543 hospitalized patients were screened of which 743 were treated with AB (29.2%). Included
AB users had a mean age of 68 yr (range 16–99) and 52% were male. Penicillins were mostly used (63%) and 19%
received more than one AB. AAD was observed in 9.6% of AB users including 4 with confirmed Clostridium difficile
infection. AAD started between 1 and 16 days after AB start (median 5) and had a duration of 2 to 41 days (median
4). AAD was significantly associated with higher age and the use of double AB and proton pump inhibitors. AAD
patients had extra laboratory investigations (79%), received extra pharmacological treatment (42%) and 10 of them
were isolated (14%). AAD related extra nursing time amounted to 51 minutes per day for the treatment of diarrhea.
Conclusions: In this observational study, with one third of hospitalized patients receiving AB, an AAD period
prevalence of 9.6% in AB users was found. AAD caused extra investigations and treatment and an estimated extra
nursing care of almost one hour per day. Preventive action are highly recommended to reduce the prevalence of
AAD and associated health care costs.
Keywords: Antibiotic use (AB), Antibiotic associated diarrhea (AAD), Clostridium difficile infection, AB use point
prevalence, AAD prevalence, Contamination control, AAD related nursing careBackground
In Europe, about one third of patients receives antibiotic
(AB) therapy during hospitalization. Highest frequencies
of AB treatment are observed in intensive care units and
in surgical and internal medicine departments [1]. A
common adverse effect of AB treatment is the development
of antibiotic-associated diarrhea (AAD) with symptoms* Correspondence: monique.elseviers@uantwerpen.be
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unless otherwise stated.ranging from mild to severe attacks [2]. Most of the cases
are benign and resolve under symptomatic treatment.
Particularly if the diarrhea is associated with a Clos-
tridium difficile infection, symptoms are more severe
and can lead to a fulminant, relapsing and occasionally
fatal colitis [3]. AAD, and particularly the more severe
forms of Clostridium difficile infection, may result in in-
creased diagnostic procedures, extended hospital stay and
increased medical care costs [4,5].
The global prevalence of AAD, with inclusion of the mild
to moderate attacks without further clinical diagnosticl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pending on the antibiotic used, the epidemiological setting
and the host [3]. Increased frequencies are found in chil-
dren and advanced age. Additionally, underlying illness, re-
cent surgery and drugs that alter bowel motility are factors
that increase the risk of AAD development [2]. Reported
prevalence ranges from 3.2 to 29.0%. Based on a recently
published meta-analysis of RCTs investigating the value of
probiotics for the prevention of AAD, we calculated a
weighted prevalence of AAD of 14% in the control popula-
tions [6]. Among all AAD cases, 10 to 20% are associated
with Clostridium difficile infection [7] resulting in a mean
estimated incidence in Belgian hospitals of 0.91 per 1000
hospital admissions in 2011 [8].
Using the methodology of a point prevalence investiga-
tion to check for antibiotic use, this study aims to measure
the period prevalence of AAD in hospitalized patients in
the northern part of Belgium and to document the associ-
ated diagnostic investigations, contamination control and
extra nursing care for the treatment of diarrhea.
Methods
In all adult patients, hospitalized in one of the internal
medicine wards of four participating hospitals, a point
prevalence methodology was used to screen for AB use
(Figure 1). Charts from all patients treated with AB on the
observation day were investigated for signs and symptoms
of AAD on that day as well as in the week before and the
week after (period prevalence). In patients with AAD, re-
lated diagnostic procedures, contamination control, AAD
treatment and extra nursing care were registered.
Setting
One university hospital and three associated regional
hospitals in the northern part of Belgium participated.Figure 1 Screening procedure for inclusion of antibiotic users (= point
prevalence of AAD).Within these hospitals, all wards of the internal medicine
department were included with exception of pediatric
wards.
Selection of patients
During the study period (January-April 2013), a research
nurse visited all participating wards at time intervals of
10 to 14 day between observations. At each observation
day, all hospitalized patients were screened for AB use.
Patients were included in the study if over 16 years, hos-
pitalized at the participating ward and treated with AB
at the observation day (Figure 1).
Sample size calculation
During the study period, an occupation rate of 20 pa-
tients per ward was expected. Given a total of 19 partici-
pating wards, about 380 patients could be screened for
AB treatment at each observation day, resulting in a
total of 2660 patients screened at the end of the study
(i.e. after 8 observation days). With an expected fre-
quency of 30% of patients treated with AB [1], 798
patients were expected to be included. Based on the
estimation of 14% of patients that might develop AAD
[6], the total number of AAD patients eligible for obser-
vations of AAD related diagnostic procedures and
treatment would be 112. Using this sample size, the esti-
mation of a 14% prevalence of AAD would have a 95%
confidence interval of 11.6-16.4.
Data collection
A patient checklist was used by the nurse researcher to
collect data on personal characteristics (age, gender,
ADL, dementia), hospitalization admission and discharge
dates, AB treatment (start and stop date, type of AB pre-
scribed) and clinical conditions known to increase theprevalence of AB use) and antibiotic associated diarrhea (= period
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bowel disease, diabetes, COPD, HIV, transplantation,
chemotherapy, radiotherapy, endoscopy, abdominal sur-
gery, use of proton pump inhibitors and nasogastric
tubes) [2,3,9]. In case of diarrhea, start and stop dates
were noted together with associated diagnostic proce-
dures (laboratory tests, endoscopy, etc.), contamination
control and diarrhea treatment (IV hydration, medica-
tion). AAD related investigations and treatments were
collected for the entire duration of AAD.
Additionally, a checklist of nursing care for patients
with diarrhea was completed by the treating nurses from
the day of inclusion up to a maximum of seven consecu-
tive days or until the end of the diarrhea period. Nurses
noted per day of treatment the frequency of all extra
care associated to diarrhea.
Diagnosis of AAD
A chart review of the nursing files of all included AB pa-
tients, completed with information from the treating nurse,
was performed aiming to identify signs and symptoms of
diarrhea. In all included wards, it is part of the clinical
practice to screen daily for diarrhea and to note the results
of the screening in the patient’s nursing files. The period
prevalence of AAD was estimated by screening the charts
of patients for diarrhea at the day of inclusion (= the obser-
vation day) as well as in the week before the inclusion day
and the week after the inclusion day (Figure 1). Date of
start and discontinuation of AB treatment as well as date
of first signs and end of diarrhea were carefully noted.
The diagnosis of AAD was based on the most com-
monly used definition found in literature [2,3,6,10].
Based on the collected data, patients were considered as
having diarrhea if a change in normal stool frequency
was observed with at least three loose or watery stools
per day for at least two consecutive days. Additionally,
start dates of AB use and the development of diarrhea
were compared and the diagnosis of AAD was made
when the first signs and symptoms of diarrhea occurred
after the start of AB use.
AAD related nursing care
We compiled a list of all possible extra nursing care actions
related to diarrhea. The list was developed by the research
nurses in collaboration with their colleagues, all working
in the internal medicine department. Selected diarrhea re-
lated actions were: (1) assistance to go to the bathroom,
(2) assistance for using a bedpan, (3) extra hygienic care,
(4) replacement of bed linen, (5) replacement of incontin-
ence material, (6) prevention of moisture injuries, (7)
treatment of moisture injuries and (8) care for hydration.
Apart from the checklist used to register the frequency
of extra nursing actions related to the care of diarrhea, a
separate investigation was performed to estimate theworking time needed to perform these extra actions. For
this purpose 18 nurses working at internal medicine
wards filled in a separate questionnaire with their esti-
mation of the time needed to perform each of the regis-
tered actions. This data was analyzed by calculating the
median, mean and trimmed mean time of care. Results
were presented to an expert panel of 6 experienced
nurses with a master degree and working in internal
wards. Finally, standard time needed to perform each ac-
tion was reached by consensus.
Statistical analysis
Data analysis was performed using the statistical package
IBM SPSS statistics, version 20.0 [11]. Mainly descriptive
statistical methods were used to calculate the prevalence of
AAD and to describe patient characteristics, associated risk
factors, clinical course of diarrhea, diagnostic procedures
and treatment of AAD patients. Differences in characteris-
tics between AAD and non-AAD patients were analyzed
using independent sample t-test (or Mann–Whitney-U test
for skewed distributions) and chi-square test for means
and proportions respectively. Logistic multiple regression
analysis was performed to investigate risk factors associ-
ated with the development of AAD.
The time spent on diarrhea associated nursing care
was calculated by multiplying the frequency registered
for each action over the entire AAD observation period
by the standard time for each action. The sum of total
time spent to each action was divided by the number of
observation days to obtain a daily mean time of AAD re-
lated nursing care. A level of significance of p < .05 and
a confidence interval of 95% were used.
Ethical considerations
Approval by the local ethical commission was given in Janu-
ary 2013 (EudractB009201216119/ECapproval4105s and B.
U.N. 143201215730). Since inclusion of the total eligible
population is a basic requirement for a trustful prevalence
measurement, we had a long discussion with both ethical
commissions to obtain a special permission to perform this
study without informed consent. Permission was obtained
under the condition that (1) the researchers had no any dir-
ect patient contact, (2) data were provided by the treating
nurse based on the medical chart, and (3) data were com-
pletely anonymized before handed over to the researcher.
Results
Description of the study population
In the 19 participating wards of internal medicine, a
total of 2543 hospitalized patients were screened and in
743 AB use was registered at the observation days, re-
vealing a point prevalence of 29.2%. Included AB users
had a mean age of 67.7 years (range 16–99), 51.5% were
male and patients were hospitalized for a median of 15
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(see Table 1). In about half of the patients, antibiotic
treatment was initiated for a respiratory tract infection.
Only 4 out of 743 AB users (0.5%) received an additional
prescription of probiotics as prevention. AB treatment
had a median duration of 6 days (mean 7.3; range 2–41).
Prevalence of antibiotic associated diarrhea (AAD)
In 98 of the 743 included AB users, signs and symptoms of
diarrhea were noted (13.2%). Diarrhea developed after the
start of AB treatment in 71 of them, giving a periodTable 1 Description of the population
Total sample of
AB users n = 743
Demographics characteristics
Age (yrs) mean (range) 67.7 (16-99)
Gender% male 51.5%
Clinical characteristics
Transfer from other ward 16.5%
ADL score (6-24) mean (SD) 12.3 (5.7)
Disorientation score (2-8) mean (SD) 2.9 (1.7)
Risk factors for diarrhea
Inflammatory bowel disease 7.3%
Proton pump inhibitors 54.6%
Chemotherapy 6.2%
Radiotherapy 2.0%
Tube feeding 3.9%
Endoscopic procedures 15.9%
Abdominal surgery 3.1%
Diabetes 26.6%
COPD 25.4%
HIV 1.2%
Transplantation 3.0%
Decubitus 0.4%
Laxatives 15.8%
Risk score (sum of factors) mean (SD) 1.5 (1.1)
Antibiotic use before diarrhea
More than one antibiotic prescribed 19.2%
Type of antibiotics*
Penicillins 63.1%
Quinolones 22.2%
Cephalosporins 11.8%
Macrolides 8.1%
Aminoglycosides 3.4%
Sulfonamides 1.7%
Other ab 7.3%
*Type of antibiotics > 100% due to double and triple use.prevalence of AAD of 9.6% (95% CI = 7.5-11.9%). The ob-
served AAD prevalence varied between 4.2% in a ward of
neurology to 18.8% in a ward of nephrology. Particularly in
the wards of neurology, gastroenterology and geriatrics,
large differences were observed between the prevalence of
diarrhea from all causes and AAD (Figure 2). AAD preva-
lence varied also considerably between different age cat-
egories ranging from 5.9% in patients younger than 65 to
12.8% in patients over 85 (Figure 3). First signs and symp-
toms of AAD were observed between 1 and 16 days after
the start of AB treatment (median 5). A large variation ofComparison between nonAAD and AAD patients
nonAAD n = 672 AAD n = 71 p value of
difference
67.3 (18.1) 71.9 (16.8) 0.040
47.9% 53.5% 0.369
16.4% 16.9% 0.917
12.0 (5.6) 14.2 (5.8) 0.002
2.9 (1.6) 3.5 (1.9) 0.001
7.4% 5.6% 0.577
53.1% 69.0% 0.011
6.0% 8.5% 0.406
1.8% 4.2% 0.165
3.6% 7.0% 0.151
14.9% 25.4% 0.022
2.8% 5.6% 0.194
25.7% 35.2% 0.086
25.7% 22.5% 0.555
1.2% 1.4% 0.873
3.0% 2.8% 0.940
0.1% 2.8% 0.001
16.4% 10.9% 0.260
1.5 (1.1) 1.9 (1.1) 0.001
18.0% 31.0% 0.008
62.9% 64.8% 0.760
21.6% 28.2% 0.204
12.1% 9.9% 0.586
8.2% 7.0% 0.737
3.6% 1.4% 0.336
1.8% 1.4% 0.818
7.0% 9.9% 0.376
Figure 2 Period prevalence of diarrhea and antibiotic-associated diarrhea (AAD) in hospitalized patients with antibiotic treatment (n = 743)
according to the ward of admission.
Figure 3 Period prevalence of diarrhea and antibiotic-associated diarrhea (AAD) in hospitalized patients with antibiotic treatment (n = 743)
according to age categories.
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The duration of AAD varied between 2 and 41 days (me-
dian 4; mean 4.9). Four patients were confirmed to have a
Clostridium difficile infection with a median duration of
diarrhea of 10 days (mean 11,0; range 10–13).Comparison between non-AAD and AAD patients
Patients with AAD were older, used more different anti-
biotics, had more problems with activities of daily living
(higher ADL score), showed more disorientation in time
and place (higher disorientation score) and had more
risk factors associated with the development of AAD
compared to non-AAD patients (see Table 1, comparison
between AAD and non-AAD patients). Particularly a sig-
nificant higher use of proton pump inhibitors, endo-
scopic procedures and decubitus was found in AAD
patients. The type of antibiotics used by AAD and non-
AAD patients did not differ.
Patients with AAD had a significant (p = 0.008) longer
hospital stay compared to non-AAD patients with a me-
dian (range) of 21(5–122) and 14(1–238) days, respectively.Characteristics associated with the development of
antibiotic associated diarrhea
In the univariate analysis, several demographic and clin-
ical patients’ characteristics as well as previously re-
ported risk factors and a particular type of ward were
associated with the development of AAD (see Table 2).
In the multivariate analysis the following characteristics
were identified as independent risk factors for AAD: in-
creased age, using more than one AB, increased ADL
and disorientation scores, use of proton pump inhibitors,
presence of decubitus and being hospitalized at a ward
of nephrology. These factors had a limited Nagelkerke rTable 2 Risk factors associated with the development of
AAD
Univariate Multivariate*
Associated factors OR (95% CI) OR (95% CI)*
Age > 70y 2.22 (1.30-3.77) 2.41 (1.39-4.18)
More than one AB 2.05 (1.19-3.51) 2.27 (1.30-3.98)
ADL score (6-24) 1.07 (1.02-1.11)
Disorientation score (2-8) 1.23 (1.09-1.39)
Risk score (sum of risk factors) 1.42 (1.14-1.75)
Proton pump inhibitors 1.97 (1.16-3.32) 1.98 (1.15-3.43)
Endoscropic procedures 1.94 (1.09-3.45)
Diabetes 1.57 (0.94-2.63)
Decubitus 19.45 (1.74-217.24) 32.11 (2.82-366.13)
University Hospital 1.70 (1.03-2.80)
Nephrology 2.50 (1.34-4.67) 2.34 (1.23-4.47)
*Nagelkerke Rsquare = 0.103.square of 0.103 in the explanation of the variation in
AAD development.Investigation of antibiotic associated diarrhea
In 79% of AAD positive patients, a baseline bacterio-
logical investigation was performed with 23 patients re-
ceiving a standard culture (2 positive results) and 48
patients receiving a first specific investigation for Clos-
tridium difficile (4 positive results). Additional standard
tests were performed in 4 patients. Additional tests for
Clostridium difficile were performed in 13 patients (all
with negative test results during the baseline investiga-
tion) with 4 even having a third and 1 with a fourth test.
All these additional investigations tested negative for
Clostridium difficile (Table 3).Treatment of antibiotic associated diarrhea
Only one of the AAD positive patients received an extra
diagnostic investigation (endoscopy). Patient isolation
(all with transfer to a single room) was applied in 10 pa-
tients (14% of AAD patients), including those four pa-
tients tested positive for Clostridium difficile. The
median duration of isolation was 10 days. Pharmaco-
logical treatment of AAD was applied in 19 patients
(27% of AAD patients) and consisted in the discontinu-
ation of the original AB treatment (3 patients) and the
prescription of probiotics (9 patients), antidiarrheals (9
patients), antibiotics (1 patients) and antiparasitic prod-
ucts (3 patients). Additionally, 11 patients received IV
hydration (Table 3). Among the four patients with
Clostridium difficile infection, pharmacological treat-
ment was limited to one patient receiving an antipara-
sitic product, one patient receiving one antiparasitic andTable 3 AAD related outcome and actions
AAD related investigations n = 71
Standard bacteriological investigations (n) 27
Specific for clostridium (n) 66
Other bacteriological investigations (n) 6
Additional investigations (endoscopy) (n) 1
AAD related treatment n = 71
Patient isolation in single room (n) 10
Pharmacological treatment
-Probiotics (enterol) (n) 9
-Antidiarrheal (loperamide) (n) 9
-Antibiotics (n) 1
-Antiparasitics (flagyl) (n) 3
IV hydration (n) 12
AAD related nursing care
Extra daily nursing care time median (range) 51.3 (5-154)
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hydration.
Extra nursing care related to antibiotic associated
diarrhea
Observations of diarrhea related care were performed in
26 patients spread over 94 days with diarrhea. Patients in-
cluded in this observation were somewhat older with a
mean age of 75 (range 49–93), had a longer length of stay
with a mean of 20 days (range 4–49) and had a longer
period of diarrhea with a mean of 10 days (range 2–41).
The standard time needed to perform each of the extra
diarrhea related actions ranged from 3 minutes for the care
of hydration to 15 minutes for assistance to go to the bath-
room and for extra hygienic care (Figure 4). The total time
spent to deliver the extra nursing care related to diarrhea
treatment amounted to a median of 51 minutes per day
(range 5–154). As shown in Figure 4, the most frequent
extra action performed was the replacement of incontin-
ence material with a median of 2.2 replacements per day
(range 0–6). The replacement of incontinence material was
also the most labor intensive with a median time spent of
10.8 minutes per day (range 0–30).
Discussion
Our study revealed that one out of three patients hospi-
talized in internal medicine departments received ABFigure 4 Extra nursing care related to the treatment of patients with
per action per day. Frequency and estimation of nursing time spent to ea
spread over 94 AAD days. Unit time = estimated time (in minutes) needed
performed per patient and per day.treatment. Of these 743 AB users, 9.6% developed diar-
rhea that could be associated to AB use. Half of the pa-
tients with diarrhea underwent biological testing for
Clostridium difficile (4 positive) and 10 patients were
isolated.
Strengths and limitations
A literature research revealed that reported incidences of
AAD were undetermined showing a wide variation be-
tween population studies and clinical trials (reviewed by
McFarland, 2008) [2]. The main contribution of this study
is that our primary objective was to determine the overall
prevalence of AAD (including uncomplicated cases) in all
patients hospitalized in internal medicine departments and
treated with AB. Moreover, we used a methodology enab-
ling to distinguish patients being treated with antibiotics
for diarrhea and patients developing diarrhea after the start
of antibiotic treatment. By carefully documenting the start
time of AB treatment and first symptoms of diarrhea, we
had to exclude 27 patients (out of 98) with diarrhea from
the AAD group since first signs of their diarrhea were ob-
served before the start of AB treatment.
Based on control groups of clinical trials included in a re-
cent review by Hempel and colleagues [6], we calculated a
weighted prevalence rate of 14%. In our AAD study we
found a lower prevalence of 9.6%. There are several rea-
sons to think that our study slightly underestimated theantibiotic-associated diarrhea (AAD) expressed as total time spent
ch action was based on observations in 26 AAD positive patients
to perform this action. Freq day = median frequency of the action
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tection of diarrhea were limited to seven days post inclu-
sion, while first signs and symptoms might have occurred
later on. Second, we found a slightly higher prevalence in
the university hospital where an electronic patient chart
was used with the requirement to register nursing related
problems per shift. It might be that this rigorous electronic
registration system enabled faster and more complete
registration of diarrhea (compared to the handwritten chart
in the other hospitals), particularly in case of mild symp-
toms over a limited time period.
Most health economic studies investigating the health
care costs associated with AAD, concentrated on Clostrid-
ium difficile associated cases [4,5]. Positive in our study
was to focus on all AAD patients and to study extra nurs-
ing care for the treatment of diarrhea. Our observation that
caring for a patient with diarrhea is rather labor intensive
(amounting to 51 extra minutes of care per day) seems
worthwhile to take into account in future health economic
evaluations of AAD. Limitations were that (1) we only esti-
mated the time spent per day for this extra treatment (not
including cost calculations or extra requirements for pa-
tient isolation), and that (2) observations were limited to
patients showing clear signs and symptoms of diarrhea at
the observation day. As a result, patients included in this
subsample had a longer median duration of diarrhea com-
pared to patients in the complete sample.
General discussion
Our point prevalence measurement of 29.7% of AB users is
comparable with the results of the ESAC survey in Euro-
pean hospitals using the same methodology [1]. Based on a
sample of 5 hospitals per country and including 37352 ad-
mitted patients in the ESAC project, a global point preva-
lence of AB treatment of 28.6% was registered, increasing
to 29.8% in internal medicine and to 58,3% in intensive
care units. For Belgium, ESAC reported an overall point
prevalence of 27.7% in 2009.
In our sample, 4 patients screened positive for Clostrid-
ium difficile. Comparing this figure proved difficult as pub-
lished rates are calculated in a variety of ways, using
different denominators. In the review of McFarland [2], in-
cidence rates for Clostridium difficile associated diarrhea
ranged from 3.5/10000 to 18.5%. Asha and colleagues
started from a sample of fecal specimens systematically
tested for Clostridium difficile cytotoxins and reported a
prevalence of 12.7% [9]. On the other hand, the Belgian
Scientific Institute for Public Health found an incidence of
0.91 per 1000 hospital admissions based on collected re-
ports of collaborating Belgian hospitals [12]. Depending on
the denominator, we can present the incidence of the 4
positive patients of our study as 0.16% (4/2,543 patients
screened during the observation days), 0.54% (4/743 pa-
tients with AB at the observation days) or 5.63% (4/71patients with AAD). A more uniform system to report inci-
dences with clear information about the denominator used
is highly recommended in this domain.
Several health economic studies focused on the health
care costs related to Clostridium difficile associated
diarrhea showing that these patients had a significant
increase in hospital costs mainly associated to a longer
length of stay [4,13,14]. Dubberke and colleagues pointed
to the additional increased health care costs observed 6
months after the initial hospitalization period [5]. In
health economic studies, the costs associated to the much
more prevalent but less severe AAD cases were not in-
cluded. In our study, we took a first step to this calculation
with the estimation of the extra nursing time spent for the
treatment of AAD patients enabling to calculate associ-
ated extra costs for nursing care and material in a later
phase of our study. In the study we also observed differ-
ences in the total hospital length of stay in AAD and
non-AAD patients. Among AAD patients, those with a
Clostridium difficile infection had a median hospitalization
of 43.5 days (range 24–51). These differences in length of
stay are not corrected for any confounding factors and
needs further analysis.
Our study showed that probiotics were very rarely used
for the prevention of AAD with only 4 out of 743 AB users
(0.5%) receiving a probiotic treatment before the occur-
rence of diarrhea. The use of probiotics (particularly the
non-pathogenic yeast Saccharomyces boulardii) for the
prevention of AAD gained increasing attention in recent
years [10,15]. Meta-analyses of studies focusing on the pre-
vention of AAD in general revealed that preventive treat-
ment with Saccharomyces boulardii halved the risk of
AAD development [6,16,17]. In the light of these promis-
ing results, a cost-effectiveness analysis of preventive pro-
biotic use in AB users is highly recommended to support a
more generalized use of probiotics in clinical practice.
Conclusions
In this study, with one third of hospitalized patients re-
ceiving AB treatment, an AAD period prevalence of
9.6% in AB users was found. AAD was associated with
extra investigations, extra treatment and extra time of
nursing care of almost one hour per day. Preventive ac-
tions are highly recommended to reduce the prevalence
of AAD and associated health care costs.
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